Theolytics
Generated by Meeveem AI
"Developing next generation oncolytic viral immunotherapies to combat solid tumours in cancer patients."
Oxford
•11 - 50 Employees
•Biotechnology
About Theolytics
Theolytics is a clinical stage biotechnology company focused on developing transformative oncolytic immunotherapies for cancer. The company uses its proprietary ADENOVO discovery platform to harness viruses that selectively target and destroy cancer cells while activating the immune system to detect and clear tumours. This approach addresses the challenge of solid tumours, particularly in hard to treat cancers like ovarian cancer, where traditional therapies often fall short. The company's lead candidate, THEO-260, is specifically designed to penetrate stromal rich tumour environments and is currently in Phase I and IIa clinical trials across Europe and the United States. By combining world leading expertise in virology, cancer biology, and immunology, Theolytics is working to deliver innovative therapies that offer patients lasting cures rather than temporary relief.
32
Team Members
2017
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where every cancer patient can access innovative therapies that deliver lasting cures, breaking through the barriers posed by difficult to treat solid tumours.
Our Mission
At Theolytics, our mission is to improve the lives of people impacted by cancer through the development of transformative oncolytic immunotherapies.